Choice of clinical outcomes in randomized trials of heart failure therapies: Disease-specific or overall outcomes?

American Heart Journal

Volumn 143, Issue 1, 2002, Pages 22-28

  Yusuf, Salim ^a   Negassa, Abdissa ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; HEART FAILURE; HIGH RISK PATIENT; HUMAN; METHODOLOGY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REPRODUCIBILITY; RISK BENEFIT ANALYSIS;

EID: 0036141025     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.119770     Document Type: Article

References (9)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: The SOLVD investigators
2. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
3. Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology
4. The analysis of discrete and continuous longitudinal data
5. Marginal analysis of recurrent events and a terminating event
6. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: A meta-analysis of over 100,000 patients
7. Obtaining medically meaningful answers from an overview of randomized clinical trials
8. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials